Daily Archives: 22/04/2017

Compulsory license

A compulsory license provides that the owner of a patent or copyright licenses the use of their rights against payment either set by law or determined through some form of adjudication or arbitration. In essence, under a compulsory license, an individual or company seeking to use another’s intellectual property can do so without seeking the […]

Societal views on patents

Legal scholars, economists, activists, policymakers, industries, and trade organizations have held differing views on patents and engaged in contentious debates on the subject. Critical perspectives emerged in the nineteenth century that were especially based on the principles of free trade.[1]:262–263 Contemporary criticisms have echoed those arguments, claiming that patents block innovation and waste resources that […]


Evergreening is any of various legal, business and technological strategies by which producers extend their patents over products that are about to expire, in order to retain royalties from them, by either taking out new patents (for example over associated delivery systems, or new pharmaceutical mixtures), or by buying out, or frustrating competitors, for longer […]


A biosimilar (also known as follow-on biologic or subsequent entry biologic) is a biologic medical product which is almost an identical copy of an original product that is manufactured by a different company.[1] Biosimilars are officially approved versions of original “innovator” products, and can be manufactured when the original product’s patent expires.[2] Reference to the […]

Bayh-Dole Act

Government Patent Policy Act of 1980 Patent and Trademark System Reform Long title An Act to amend the patent and trademark laws. Nicknames Patent and Trademark Law Amendments Act Enacted by the 96th United States Congress Effective December 12, 1980 Citations Public law 96-517 Statutes at Large 94 Stat. 3015 Codification Acts amended  Patent Act […]

Anti-Counterfeiting Trade Agreement

ACTA Anti-Counterfeiting Trade Agreement French: Accord commercial anti-contrefaçon Spanish: Acuerdo Comercial Anti-Falsificación {{{image_alt}}} Type Plurilateral agreement Drafted  15 November 2010 (final revision)[1] 15 April 2011 (formal publication)[2] Signed 1 October 2011 Location Tokyo, Japan Effective Not in force Condition Ratification by six states Negotiators   Australia  Canada  European Union  Japan  Mexico  Morocco  New Zealand  Singapore  South […]

Generic drug

In some countries, such as Brazil (photo) and France, more than 20% of all drug sales are generic. A generic drug is a pharmaceutical drug that is equivalent to a brand-name product in dosage, strength, route of administration, quality, performance, and intended use.[1] The term may also refer to any drug marketed under its chemical […]

Counterfeit medications

A counterfeit medication or a counterfeit drug is a medication or pharmaceutical product which is produced and sold with the intent to deceptively represent its origin, authenticity or effectiveness. A counterfeit drug may contain inappropriate quantities of active ingredients, or none, may be improperly processed within the body (e.g., absorption by the body), may contain […]


The problem is compounded by the fact that there are very few branded medicines in india , the rest can be called branded generics .Also there are numerous compounds for which there are no so called branded generics. Branded molecules are those which are patented, branded generic being brands made after expiry of patent and […]